Myeloproliferative neoplasm-driving Calr frameshift promotes the development of pulmonary hypertension in mice
- PMID: 33785036
- PMCID: PMC8011226
- DOI: 10.1186/s13045-021-01064-8
Myeloproliferative neoplasm-driving Calr frameshift promotes the development of pulmonary hypertension in mice
Abstract
Frameshifts in the Calreticulin (CALR) exon 9 provide a recurrent driver mutation of essential thrombocythemia (ET) and primary myelofibrosis among myeloproliferative neoplasms (MPNs). Here, we generated knock-in mice with murine Calr exon 9 mimicking the human CALR mutations, using the CRISPR-Cas9 method. Knock-in mice with del10 [Calrdel10/WT (wild-type) mice] exhibited an ET phenotype with increases of peripheral blood (PB) platelets and leukocytes, and accumulation of megakaryocytes in bone marrow (BM), while those with ins2 (Calrins2/WT mice) showed a slight splenic enlargement. Phosphorylated STAT3 (pSTAT3) was upregulated in BM cells of both knock-in mice. In BM transplantation (BMT) recipients from Calrdel10/WT mice, although PB cell counts were not different from those in BMT recipients from CalrWT/WT mice, Calrdel10/WT BM-derived macrophages exhibited elevations of pSTAT3 and Endothelin-1 levels. Strikingly, BMT recipients from Calrdel10/WT mice developed more severe pulmonary hypertension (PH)-which often arises as a comorbidity in patients with MPNs-than BMT recipients from CalrWT/WT mice, with pulmonary arterial remodeling accompanied by an accumulation of donor-derived macrophages in response to chronic hypoxia. In conclusion, our murine model with the frameshifted murine Calr presented an ET phenotype analogous to human MPNs in molecular mechanisms and cardiovascular complications such as PH.
Keywords: CALR; Essential thrombocythemia; Macrophage; Myeloproliferative neoplasms; Pulmonary hypertension.
Conflict of interest statement
T.Y.’s and K.S.’s department receives support from Janssen Pharmaceutical K.K., Japan. T.M.’s department receives support from Fukuda Denshi Co., Ltd., Japan. These companies were not associated with the contents of this study.
Figures
Similar articles
-
Myeloproliferative Neoplasms With Calreticulin Mutations Exhibit Distinctive Morphologic Features.Am J Clin Pathol. 2016 Mar;145(3):418-27. doi: 10.1093/ajcp/aqw005. Am J Clin Pathol. 2016. PMID: 27124925
-
CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.Am J Clin Pathol. 2015 May;143(5):635-44. doi: 10.1309/AJCPUAAC16LIWZMM. Am J Clin Pathol. 2015. PMID: 25873496
-
CALR frameshift mutations in MPN patient-derived iPSCs accelerate maturation of megakaryocytes.Stem Cell Reports. 2021 Nov 9;16(11):2768-2783. doi: 10.1016/j.stemcr.2021.09.019. Epub 2021 Oct 21. Stem Cell Reports. 2021. PMID: 34678208 Free PMC article.
-
Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib.Leukemia. 2017 May;31(5):1136-1144. doi: 10.1038/leu.2016.308. Epub 2016 Nov 3. Leukemia. 2017. PMID: 27807369 Free PMC article.
-
Knock-in of murine Calr del52 induces essential thrombocythemia with slow-rising dominance in mice and reveals key role of Calr exon 9 in cardiac development.Leukemia. 2020 Feb;34(2):510-521. doi: 10.1038/s41375-019-0538-1. Epub 2019 Aug 30. Leukemia. 2020. PMID: 31471561
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
